Minerva gastroenterology最新文献_第5页

Primary sclerosing cholangitis and inflammatory bowel disease: a complicated yet unique relationship. 原发性硬化性胆管炎和炎症性肠病：一种复杂而独特的关系。

Minerva gastroenterology Pub Date : 2024-02-07 DOI: 10.23736/S2724-5985.23.03605-7

Matteo Peviani, Nora Cazzagon, Martina Gambato, Luisa Bertin, Fabiana Zingone, Edoardo V Savarino, Brigida Barberio

引用次数: 0

The influence of acupoint scraping combined with traditional Chinese medicine fumigation on gastrointestinal dysfunction and defecation after minimally invasive abdominal surgery. 穴位刮痧联合中药熏蒸对腹部微创手术后胃肠功能紊乱及排便的影响

Minerva gastroenterology Pub Date : 2024-01-29 DOI: 10.23736/S2724-5985.23.03621-5

Min Su, Wanchen Yu, Ying Su

引用次数: 0

Specific probiotics and prebiotics to improve the quality of life of patients with chronic irritable bowel syndrome. 改善慢性肠易激综合征患者生活质量的特定益生菌和益生元。

Minerva gastroenterology Pub Date : 2024-01-19 DOI: 10.23736/S2724-5985.23.03563-5

Lorenzo Bertani, Linda Balestrini, Lucia Chico, Giulia Della Scala, Francesca Geri, Alessandro Tornar, Claudio Belcari

{"title":"Specific probiotics and prebiotics to improve the quality of life of patients with chronic irritable bowel syndrome.","authors":"Lorenzo Bertani, Linda Balestrini, Lucia Chico, Giulia Della Scala, Francesca Geri, Alessandro Tornar, Claudio Belcari","doi":"10.23736/S2724-5985.23.03563-5","DOIUrl":"https://doi.org/10.23736/S2724-5985.23.03563-5","url":null,"abstract":"Background: Irritable bowel syndrome (IBS) is a chronic disorder with an important impact on patients' quality of life. Although several data indicate that psychological symptoms are frequently reported by patients with IBS, few therapies have been evaluated regarding these issues.Methods: A retrospective observational study was conducted to evaluate the effectiveness of a probiotic-based dietary supplement (Colicron®) in a group of patients with diarrhea-predominant IBS (IBS-D). We included patients treated with Colicron® (1 cps/day for 8 weeks). Primary endpoint was the gastrointestinal symptoms' remission evaluated by Visual Analogue Scale (VAS); secondary endpoint was the impact of the treatment on physical and mental health evaluated by Hospital Anxiety and Depression Score (HADS) and Short Form Health Survey 36 (SF-36). VAS was assessed at week 4 (T4), week 8 (T8) and week 12 (T12), whereas HADS and SF-36 were performed even at the start of the Colicron® treatment (T0).Results: An improvement of VAS Score was observed at T8 (P<0.001) and T12 (P<0.05) compared to T4. Lower HADS-A (anxiety subdomain) score was obtained at each time point versus T0 (P<0.01), and higher scores of all SF-36 domains were observed during the treatment (0.05<P<0.001) compared to baseline. Moreover, HADS-D (depression subdomain) score, correlated positively, at T0 (P<0.05) and T4 (P<0.05) with the age, as well as a positive correlation was detected between disease duration (P<0.05) and age of patients (P<0.001).Conclusions: Colicron® could be useful in improving both gastrointestinal and psychological symptoms in IBS-D patients. Further prospective clinical trials are needed to confirm these preliminary data.","PeriodicalId":94142,"journal":{"name":"Minerva gastroenterology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139492853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Can dysmetabolic comorbidities carry hepatic fat accumulation in patients with inflammatory bowel diseases? 代谢紊乱合并症会导致炎症性肠病患者肝脏脂肪堆积吗？

Minerva gastroenterology Pub Date : 2024-01-19 DOI: 10.23736/S2724-5985.23.03617-3

Ludovico Abenavoli, Giuseppe Gm Scarlata, Rocco Spagnuolo, Francesco Luzza

引用次数: 0

Therapeutic success in primary biliary cholangitis and gut microbiota: a safe highway? 原发性胆汁性胆管炎的治疗成功与肠道微生物群：安全的高速公路？

Minerva gastroenterology Pub Date : 2024-01-19 DOI: 10.23736/S2724-5985.23.03590-8

Ludovico Abenavoli, Giuseppe Gm Scarlata, Emidio Scarpellini, Anna C Procopio, Francesca R Ponziani, Luigi Boccuto, Nenad Cetkovic, Francesco Luzza

{"title":"Therapeutic success in primary biliary cholangitis and gut microbiota: a safe highway?","authors":"Ludovico Abenavoli, Giuseppe Gm Scarlata, Emidio Scarpellini, Anna C Procopio, Francesca R Ponziani, Luigi Boccuto, Nenad Cetkovic, Francesco Luzza","doi":"10.23736/S2724-5985.23.03590-8","DOIUrl":"https://doi.org/10.23736/S2724-5985.23.03590-8","url":null,"abstract":"Primary biliary cholangitis (PBC) is a chronic, cholestatic, autoimmune disease, characterized by destruction of bile ducts. PBC predominantly affects women between 40 and 60 years of age. The presence of antimitochondrial antibodies (AMA) is a serological feature of PBC. These highly specific antibodies are found in about 95% of patients with the disease. The family of enzymes located in the inner membrane of the mitochondria, called the 2-oxo-acid dehydrogenase complex represents the target of the AMA. Ursodeoxycholic acid (UDCA) is a synthetic bile acid capable of protecting cholangiocytes from cholestatic damage caused by the accumulation of bile acids with a mechanism of action not yet well clarified. UDCA represents the gold standard therapy for PBC patients with recommended dose of 13-15 mg/kg/day. However, not every patient responds to therapy. On the other hand, the gut microbiota plays a key role in the onset of PBC through still unclear biochemical pathways. Less is known about its role as a potential biomarker after drug treatment. Actually, few studies analyzed the changes in gut microbiota composition before and after UDCA treatment. For this reason, this review represents an examination of the studies carried out on changes in gut microbiota composition in patients affected by PBC before and after treatment.","PeriodicalId":94142,"journal":{"name":"Minerva gastroenterology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139492855","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Twenty-five percent human albumin solution in clinical practice: indications, risks and monitoring protocols. 临床实践中的 25% 人血白蛋白溶液：适应症、风险和监测方案。

IF 1.9

Minerva gastroenterology Pub Date : 2024-01-01 DOI: 10.23736/S2724-5985.24.03826-9

Carmine Gambino, Paolo Angeli

{"title":"Twenty-five percent human albumin solution in clinical practice: indications, risks and monitoring protocols.","authors":"Carmine Gambino, Paolo Angeli","doi":"10.23736/S2724-5985.24.03826-9","DOIUrl":"10.23736/S2724-5985.24.03826-9","url":null,"abstract":"Human albumin solution is a commonly used therapeutic agent because of its ability to expand plasma volume and improve oncotic pressure in various clinical settings, such as in patients with cirrhosis and sepsis, whose management is a major challenge. Despite the lack of evidence for the superiority of human albumin solutions compared with crystalloids in improving major outcomes, short-term administration of human albumin solution appears to be more effective than both saline and plasmalyte in recovering systemic hemodynamics and achieving a lower daily net fluid balance in patients with cirrhosis and sepsis-induced hypotension. The use of 25% human albumin solution could also effectively manage ascites in patients with cirrhosis, reducing the volume of fluids administered and allowing a faster achievement of the plasma target concentration. This article aims to comprehensively review the indications for the use of human albumin solutions, examine the associated risks, and outline best practices for monitoring patients receiving this treatment, ensuring optimal patient outcomes while minimizing adverse effects.","PeriodicalId":94142,"journal":{"name":"Minerva gastroenterology","volume":"September Suppl. 1 to N. 3","pages":"1-7"},"PeriodicalIF":1.9,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142640283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Upadacitinib in Crohn's disease: real-world experience. 乌达帕替尼治疗克罗恩病：真实世界的经验。

Minerva gastroenterology Pub Date : 2023-12-21 DOI: 10.23736/S2724-5985.23.03594-5

Adil S Mir

引用次数: 0

National frequency, trends, and healthcare burden of care fragmentation in readmissions for end-stage liver disease in the USA. 美国终末期肝病患者再入院治疗的全国频率、趋势和医疗保健负担。

Minerva gastroenterology Pub Date : 2023-12-01 DOI: 10.23736/S2724-5985.22.03232-6

Olufunso Agbalajobi, Ebehiwele Ebhohon, Chineye B Amuchi, Edwige C Nzugang, Elizabeth O Soladoye, Oyedotun Babajide, Adeyinka C Adejumo

{"title":"National frequency, trends, and healthcare burden of care fragmentation in readmissions for end-stage liver disease in the USA.","authors":"Olufunso Agbalajobi, Ebehiwele Ebhohon, Chineye B Amuchi, Edwige C Nzugang, Elizabeth O Soladoye, Oyedotun Babajide, Adeyinka C Adejumo","doi":"10.23736/S2724-5985.22.03232-6","DOIUrl":"10.23736/S2724-5985.22.03232-6","url":null,"abstract":"Background: End-stage liver disease (ESLD) patients have frequent readmissions to the same facility or a different hospital (care fragmentation). Care fragmentation results in care delivery from an unfamiliar clinical team or setting, a potential source of suboptimal clinical outcomes. We examined the occurrence, trends, and association between care fragmentation and outcomes during readmissions for ESLD.Methods: From the Nationwide Readmissions Database (January to September 2010-2014), we followed adult (age ≥18 years) hospitalizations for ESLD who were discharged alive for 90 days. During 30- and 90-day readmissions, we calculated the frequency, determinants, and clinical outcomes of care fragmentation (SAS 9.4).Results: Of the 67,480 ESLD hospitalizations surviving at discharge from 2010-2014, 35% (23,872) and 52% (35,549) were readmitted in 30- and 90-days respectively. During readmissions, the frequencies of care fragmentation were similar (30-day: 25.4% and 90-day: 25.8%) and remained stable from 2010 to 2014 (P trends>0.5). Similarly, factors associated with care fragmentation were consistent across 30- and 90-day readmissions. These included ages: 18-44 years, liver cancer, receipt of liver transplantation, hepatorenal syndrome, prolonged length of stay, and hospitalization in non-teaching facilities. During 30- and 90-day readmissions, care fragmentation was associated with higher risk of mortality (adjusted mean ratio: 1.13[1.03-1.24] and 1.14 [1.06-1.23]; P values<0.0001), prolonged length of stay (4.6-days vs. 4.1-days and 5.2-days vs. 4.6-days; P values<0.0001), and higher hospital charges ($36,884 vs. $28,932 and $37,354 vs. $30,851; P values<0.0001).Conclusions: Care fragmentation is high among readmissions for ESLD and is associated with poorer outcomes.","PeriodicalId":94142,"journal":{"name":"Minerva gastroenterology","volume":"69 4","pages":"470-478"},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139405787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Role of demographics in noninvasive testing for colorectal cancer screening: do targeted cut-off values improve detection? 人口统计学在结直肠癌筛查无创检测中的作用：有针对性的临界值是否能提高检测率？

Minerva gastroenterology Pub Date : 2023-12-01 Epub Date: 2022-03-28 DOI: 10.23736/S2724-5985.22.03124-2

Inayat Gill, Christienne Shams, Angy Hanna, Julie George, Laith H Jamil, Atulkumar Patel

{"title":"Role of demographics in noninvasive testing for colorectal cancer screening: do targeted cut-off values improve detection?","authors":"Inayat Gill, Christienne Shams, Angy Hanna, Julie George, Laith H Jamil, Atulkumar Patel","doi":"10.23736/S2724-5985.22.03124-2","DOIUrl":"10.23736/S2724-5985.22.03124-2","url":null,"abstract":"Background: Fecal immunochemical test (FIT) is a yearly alternative colorectal screening modality for average risk individuals unwilling or unable to undergo invasive colorectal cancer (CRC) screening due to cost and accessibility. This study aimed to determine whether FIT should be interpreted within the context of patient demographics and medical history.Methods: Patients >50 years old who had a FIT followed by colonoscopy within 1 year were analyzed based on age, race, BMI, social and medical comorbidities. False positive (FP) and false negative (FN) FIT results within each patient demographic and medical history variable were determined by comparing with the gold standard of colonoscopy using χ2 analysis.Results: One thousand twenty-five patients were reviewed. 21.8% of FIT results were positive. Factors which differed in positive FIT rates were age (P=0.003), smoking (P<0.001), alcohol (P=0.001), and hypertension (P<0.001). The difference in rates of FP and FN FIT outcomes among each variable underwent further subanalysis. The FP was 66.8% and the FN rate was 12.8%. Higher FN outcomes were noted in those above 70, males and smokers, though the result was only statistically significant for males (P=0.009). Females were observed to have higher FP rates (P=0.019).Conclusions: Females had higher FP FIT rates compared to males, indicating that sex may influence FIT outcomes and should be accounted for when interpreting FIT results. This information can be utilized to identify populations at higher risk of FP or FN FIT results to target CRC screening. Additionally, recalculating the FP and FN rates for each variable may help determine new FIT targets.","PeriodicalId":94142,"journal":{"name":"Minerva gastroenterology","volume":"69 4","pages":"459-469"},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139405788","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction to: Intestinal fat absorption shifting: polyglucosamine biopolymer controls lipids and weight and reduces the progression of subclinical atherosclerosis. 更正：肠道脂肪吸收转移：聚葡萄糖胺生物聚合物可控制血脂和体重，减少亚临床动脉粥样硬化的发展。

Minerva gastroenterology Pub Date : 2023-12-01 DOI: 10.23736/S2724-5985.23.03598-2

Gianni Belcaro, Umberto Cornelli, Morio Hosoi, David Cox, Mark Dugall, Maria R Cesarone, Andrea Ledda, Valeria Scipione, Claudia Scipione, Beatrice Feragalli, Roberto Cotellese

引用次数: 0